Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

Completed · Phase 4 · Has a placebo group

Conditions studied: Placenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid

In brief

The purpose of this pilot study is to determine if intravenous tranexamic acid (TXA) is effective for reducing blood loss during high risk surgical procedures related to placenta previa and placenta accreta. TXA is currently used in other types of surgery for patients who are expected to have a large blood loss, such as orthopedic or open heart surgery.

Key facts

Study ID

NCT02806024

Run by

University of California, San Francisco

People needed

14

Starts

2016-11-01

Expected to finish

2018-08-01

Last updated by the study team

2019-12-03

Who can join

Age: 18 and older, up to 60. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• English and Spanish speaking pregnant women
• Any order pregnancy (singleton, twin gestation, etc)
• Suspected accreta based on ultrasound or MRI imaging studies
• All women evaluated for placenta accreta and deemed to be high risk for this disease (≥40% risk), meaning women diagnosed with a placenta previa and greater than or equal to 2 prior c-sections

You may not qualify if…

• Women less than 18 years of age
• Women with a personal history of venous or arterial thrombosis (deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke
• Women with a personal history of a high risk clotting disorder, such as anti-phospholipid syndrome
• Women who do not have a good understanding of either English or Spanish will be excluded.
• Women with defective color vision (color-blindness)

Where it is running

• Community Regional Medical Center — Fresno, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.